AbbVie Inc (ABBV)vsAveanna Healthcare Holdings Inc (AVAH)
ABBV
AbbVie Inc
$264.34
-0.29%
HEALTHCARE · Cap: $454.36B
AVAH
Aveanna Healthcare Holdings Inc
$12.41
+0.24%
HEALTHCARE · Cap: $2.93B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2374% more annual revenue ($64.39B vs $2.60B). AVAH leads profitability with a 10.6% profit margin vs 9.8%. AVAH trades at a lower P/E of 10.7x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
AVAH
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$264.34
$112.18 premium
Margin of Safety
-70.9%
Fair Value
$4.67
Current Price
$12.41
$7.74 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Earnings expanding 38.5% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 9.4x book value
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : AVAH
The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : AVAH
The primary concerns for AVAH are Price/Book, Altman Z-Score, Debt/Equity. Debt-to-equity of 5.24 is elevated, increasing financial risk.
Key Dynamics to Monitor
AVAH carries more volatility with a beta of 1.97 — expect wider price swings.
AVAH is growing revenue faster at 13.7% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 61/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Aveanna Healthcare Holdings Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?